Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ALLR | PRESS-RELEASE | neutral | 3/10 | Allarity Therapeutics announced a Trial-in-Progress poster presentation at the ESMO Gynaecological Cancers Congress 2026 | Jun 18, 2026 |
| GRCE | PRESS-RELEASE | bearish | 7/10 | Grace Therapeutics reported fiscal year 2026 results with a reduced net loss of $7.8M ($0.47/share) vs $9.6M ($0.79/shar | Jun 18, 2026 |
| PRME | PRESS-RELEASE | bullish | 6/10 | Prime Medicine announced that New Zealand's Medsafe cleared its Clinical Trial Application for PM577a, an in vivo Prime | Jun 18, 2026 |
| CMND | PRESS-RELEASE | neutral | 3/10 | Clearmind Medicine announced a new U.S. patent (No. 12,350,242) for its MEAI molecule covering binge behavior regulation | Jun 18, 2026 |
| OMER | 8-K | bullish | 5/10 | Omeros Corporation repurchased up to $16.0 million aggregate principal amount of its 9.50% Convertible Senior Notes due | Jun 18, 2026 |
| CRVO | 8-K | neutral | 4/10 | CervoMed Inc. received a USPTO notice of allowance for a new patent covering its drug candidate neflamapimod for the tre | Jun 18, 2026 |
| PFE | 8-K | neutral | 2/10 | Pfizer announced that CFO Dave Denton will step down effective August 15, 2026 to pursue a consumer goods opportunity, w | Jun 18, 2026 |
| KPRX | 8-K | bullish | 5/10 | Kiora Pharmaceuticals announced preclinical data showing its ion channel modulator KIO-300 significantly suppressed seiz | Jun 18, 2026 |
| VRXA | PRESS-RELEASE | neutral | 3/10 | VERAXA Biotech announced in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating selective killing of b | Jun 18, 2026 |
| KMDA | 6-K | neutral | 3/10 | Kamada Ltd. filed a 6-K on June 18, 2026, providing notice of its Annual General Meeting of Shareholders to be held on A | Jun 18, 2026 |
| TANH | EFFECT | bearish | 5/10 | Tantech Holdings Ltd's registration statement on Form F-3 (File No. 333-296624) became effective on June 17, 2026, under | Jun 18, 2026 |
| CUE | EFFECT | bearish | 6/10 | Cue Biopharma's S-3 shelf registration (File No. 333-296456) became effective on June 17, 2026, enabling the company to | Jun 18, 2026 |
| ISPC | EFFECT | bearish | 7/10 | iSpecimen Inc.'s S-3 registration statement (File No. 333-296512) became effective on June 17, 2026, enabling selling st | Jun 18, 2026 |
| ASRT | EFFECT | neutral | 5/10 | Assertio Holdings, Inc. received SEC effectiveness on June 17, 2026 for four separate shelf registration statements (Fil | Jun 18, 2026 |
| NCEL | EFFECT | bearish | 5/10 | NewcelX Ltd.'s shelf registration statement on Form F-3 (File No. 333-284811) became effective on June 17, 2026, per thi | Jun 18, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech closed a $98M public offering of 26.1M shares at $3.75/share and concurrently announced a $67M private placemen | Jun 18, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech completed a $98M public offering of 26,066,667 shares at $3.75 and concurrently announced a separate $67M priva | Jun 18, 2026 |
| NRSN | CLUSTER | bullish | 6/10 | CEO Alon Ben-Noon and CFO Or Eisenberg each purchased $200K worth of NRSN shares on June 16, 2026, at $0.80 per share, t | Jun 18, 2026 |
| LEGN | PRESS-RELEASE | bearish | 6/10 | Legend Biotech announced a $226M underwritten public offering of 7.7M ADSs at $29.35 per ADS, with a 30-day option for a | Jun 17, 2026 |
| MLYS | CLUSTER | neutral | 2/10 | Two insiders at Mineralys Therapeutics (MLYS) sold a combined $310K in open-market transactions over a 7-day window. The | Jun 17, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Two directors at Arcutis Biotherapeutics sold a combined $221K in open-market transactions over a 7-day window. The tota | Jun 17, 2026 |
| QURE | 144 | neutral | 3/10 | CEO and Managing Director Matthew C. Kapusta filed a Form 144 to sell 164,429 ordinary shares of uniQure N.V., with an e | Jun 17, 2026 |
| ADPT | CLUSTER | neutral | 3/10 | ADPT's Chief Scientific Officer sold $1.85M of stock in two open-market transactions within a week, the cluster's only a | Jun 17, 2026 |
| BIIB | PRESS-RELEASE | neutral | 4/10 | Biogen announced the acquisition of private biotech RayThera for up to $1 billion (upfront plus milestone payments), add | Jun 17, 2026 |
| COAG | INSIDER-BUY | neutral | 2/10 | RA Capital Management, L.P., a 10% owner, purchased $153K of COAG shares on the open market at $24.89. The buy is trivia | Jun 17, 2026 |
| ZBIO | INSIDER-BUY | neutral | 3/10 | CEO Leon O. Moulder Jr. purchased 57,000 shares of Zenas BioPharma for $1.02M at $17.96 per share in an open-market tran | Jun 17, 2026 |
| LODE | 8-K | neutral | 2/10 | Comstock Inc. granted 1,961,986 performance stock units (PSUs) and 783,618 restricted stock units (RSUs) to employees an | Jun 17, 2026 |
| PKTX | 8-K | mixed | 5/10 | ProtoKinetix filed an 8-K reporting board changes (resignation of Edward McDonough, appointment of three new directors i | Jun 17, 2026 |
| LIFD | 8-K | neutral | 2/10 | Director Richard Morrissy resigned from LFTD Partners' board effective June 14, 2026, citing health concerns. The filing | Jun 17, 2026 |
| KYMR | 144 | bearish | 4/10 | Three Form 144 filings from Kymera Therapeutics on June 17, 2026, signal intent to sell by director Bruce Booth (11,741 | Jun 17, 2026 |